PMID- 18203284
OWN - NLM
STAT- MEDLINE
DCOM- 20080424
LR  - 20211020
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 14
IP  - 4
DP  - 2008 Jan 28
TI  - An effective vaccine against colon cancer in mice: use of recombinant adenovirus 
      interleukin-12 transduced dendritic cells.
PG  - 532-40
AB  - AIM: To investigate the effect of a vaccine with recombinant adenovirus 
      interleukin-12 (AdVIL-12) transduced dendritic cells (DCs) against colon cancer 
      in mice. METHODS: DCs and AdVIL-12 were incubated together at different time 
      intervals and at different doses. Supernatant was collected and tested for IL-12 
      by enzyme-linked immunosorbent assay (ELISA). In order to determine whether tumor 
      cell lysate-pulsed (TP) AdVIL-12/DCs enhance therapeutic potential in the 
      established tumor model, CT26 colon tumor cells were implanted subcutaneously 
      (s.c.) in the midflank of naive BALB/c mice. Tumor-bearing mice were injected 
      with a vaccination of CT26 TP AdVIL-12/DCs on d 3 and 10. As a protective colon 
      tumor model, naive BALB/c mice were immunized s.c. in their abdomens with CT26 TP 
      AdVIL-12/DCs twice at seven day intervals. After the immunization on d 7, the 
      mice were challenged with a lethal dose of CT26 tumor cells and survival times 
      were evaluated. Subsequently, cytotoxic T lymphocyte (CTL) activity and 
      interferon gamma (IFNgamma) secretion was evaluated in the immunized mice, and 
      assayed CTL ex vivo. RESULTS: Murine DCs were retrovirally transduced with 
      AdVIL-12 efficiency, and the AdVIL-12 transduced DCs secreted a high level of 
      IL-12 (AdVIL-12/DCs, 615.27+/-42.3 pg/mL vs DCs, 46.32+/-7.29 pg/mL, P<0.05). 
      Vaccination with CT26 TP AdVIL-12/DCs could enhance anti-tumor immunity against 
      CT26 colon tumor in murine therapeutic models (tumor volume on d 19: CT26 TP 
      AdVIL-12/DCs 107+/-42 mm3 vs CT26 TP DCs 383+/-65 mm3, P<0.05) and protective 
      models. Moreover, the CT26 TP AdVIL-12/DC vaccination enhances tumor-specific CTL 
      activity, producing high levels of IFNgamma in immunized mice. Ex vivo primed T 
      cells with AdVIL-12/DCs were able to induce more effective CTL activity than in 
      primed T cells with CT26 TP/DCs (E:T=100:1, 69.49%+/-6.11% specific lysis vs 
      37.44%+/-4.32% specific lysis, P<0.05). CONCLUSION: Vaccination with recombinant 
      AdVIL-12 transduced DC pulsed tumor cell lysate enhance anti-tumor immunity 
      specific to colon cancer in mice.
FAU - He, Xiao-Zhou
AU  - He XZ
AD  - Department of Surgery, The First Affiliated Hospital of Soochow University, 
      Suzhou 215006, Jiangsu Province, China.
FAU - Wang, Liang
AU  - Wang L
FAU - Zhang, Yan-Yun
AU  - Zhang YY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Cancer Vaccines)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Adenocarcinoma/*therapy
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Cancer Vaccines/*genetics
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*therapy
MH  - Dendritic Cells/physiology/*transplantation
MH  - Female
MH  - Genetic Therapy/*methods
MH  - Immunotherapy, Adoptive/methods
MH  - Interleukin-12/*genetics
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
PMC - PMC2681143
EDAT- 2008/01/19 09:00
MHDA- 2008/04/25 09:00
PMCR- 2008/01/28
CRDT- 2008/01/19 09:00
PHST- 2008/01/19 09:00 [pubmed]
PHST- 2008/04/25 09:00 [medline]
PHST- 2008/01/19 09:00 [entrez]
PHST- 2008/01/28 00:00 [pmc-release]
AID - 10.3748/wjg.14.532 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2008 Jan 28;14(4):532-40. doi: 10.3748/wjg.14.532.